When.com Web Search

  1. Ads

    related to: most effective carb blocker on the market today video update

Search results

  1. Results From The WOW.Com Content Network
  2. Acarbose - Wikipedia

    en.wikipedia.org/wiki/Acarbose

    Acarbose is a starch blocker. It works by inhibiting alpha glucosidase, an intestinal enzyme that releases glucose from larger carbohydrates such as starch and sucrose. It is composed of an acarviosin moiety with a maltose at the reducing terminus. It can be degraded by a number of gut bacteria. [3]

  3. Curb That Carb Overload With This Clinically-Tested Carb ...

    www.aol.com/entertainment/curb-carb-overload...

    If you’ve ever (over)eaten a big bowl of pasta, only to feel sleepy and lethargic a few minutes later, that’s known as a good old food coma. A blood sugar spike and subsequent crash can do ...

  4. See Why Reviewers Are Obsessed With This No. 1 ... - AOL

    www.aol.com/entertainment/see-why-reviewers...

    Anyone who says they don’t enjoy pasta, cookies and bread every once in a while (or more, of course) simply has to be lying! Yes, some people choose to avoid simple carbs and sugars for valid ...

  5. Anti-obesity medication - Wikipedia

    en.wikipedia.org/wiki/Anti-obesity_medication

    The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. Deaths were associated with seven products. [84] Ephedra was removed from the US market in 2004 over concerns that it raises blood pressure and could lead to strokes and death. [85]

  6. Vedolizumab - Wikipedia

    en.wikipedia.org/wiki/Vedolizumab

    The main measure of effectiveness was the proportion of patients whose symptoms improved after six weeks of treatment. Vedolizumab was shown to be more effective than placebo: 47% (106 out of 225) of patients who received vedolizumab showed an improvement in symptoms, compared with 26% (38 out of 149) of patients who received placebo.

  7. 5-HT3 antagonist - Wikipedia

    en.wikipedia.org/wiki/5-HT3_antagonist

    Palonosetron is the newest 5-HT 3 antagonist to become available in the U.S. market. It is an isoquinoline derivative, and is effective in preventing delayed CINV. [17] Palonosetron was approved by the FDA in 2003, [18] initially for intravenous use. An oral formulation was approved on August 22, 2008, for prevention of acute CINV alone, as a ...